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Summ a r y
We sequenced all protein-coding regions of the genome (the “exome”) in two family 
members with combined hypolipidemia, marked by extremely low plasma levels of 
low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) choles-
terol, and triglycerides. These two participants were compound heterozygotes for 
two distinct nonsense mutations in ANGPTL3 (encoding the angiopoietin-like 3 pro-
tein). ANGPTL3 has been reported to inhibit lipoprotein lipase and endothelial lipase, 
thereby increasing plasma triglyceride and HDL cholesterol levels in rodents. Our 
finding of ANGPTL3 mutations highlights a role for the gene in LDL cholesterol me-
tabolism in humans and shows the usefulness of exome sequencing for identification 
of novel genetic causes of inherited disorders. (Funded by the National Human Ge-
nome Research Institute and others.)
Familial hypobetalipoproteinemia is an inherited disorder of lipid metabolism defined by very low levels (<5th percentile of age- and sex-spe-cific values) of plasma apolipoprotein B and LDL cholesterol. Familial hypo-
betalipoproteinemia is genetically heterogeneous.1,2 The best-characterized cases have 
been linked to mutations in the gene encoding apolipoprotein B (APOB) that lead to 
less apolipoprotein B synthesis and reduced secretion of very-low-density lipopro-
tein (VLDL) from the liver. As a consequence of impaired hepatic export of VLDL, 
persons with familial hypobetalipoproteinemia due to a deficiency of apolipopro-
tein B are prone to hepatic steatosis.3,4 Persons with hypobetalipoproteinemia may 
also have fat malabsorption due to impaired incorporation of dietary fats into chy-
lomicrons in the absorptive cells of the intestine.
In a number of families with familial hypobetalipoproteinemia,5 sequencing of 
APOB has failed to identify mutations, and linkage analyses have pointed to other 
chromosomal regions.6,7 Furthermore, despite family members having plasma apo-
lipoprotein B and LDL cholesterol levels as low as those of persons with mutations 
in APOB, they do not appear to have a greater susceptibility to hepatic steatosis or 
gastrointestinal symptoms than their unaffected relatives.8 To date, efforts to iden-
tify the gene defects in these families have not been successful.
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Exome sequencing (i.e., sequencing of all pro-
tein-coding regions of the genome) in a few af-
fected persons has proved successful at uncovering 
novel causal mutations in genetic disorders.9-11 
This technique is considered to be unbiased — it 
does not focus on specific genes or loci deemed 
of interest on the basis of assumptions about pos-
sible causal associations. We applied next-gener-
ation sequencing (the most recent sequencing 
methods enabling low-cost, rapid, broad sequenc-
ing) to exomes chosen on the basis of solution 
hybrid selection (a method for capturing a tar-
geted subgroup of genomic DNA) from two sib-
lings with familial hypobetalipoproteinemia not 
linked to APOB, to identify the causative gene.
Me thods
Participants
We studied a family of European descent, some 
of whose members had hypobetalipoproteinemia 
in which linkage analysis had ruled out APOB as 
the causative gene (the F kindred in the study by 
Pulai and colleagues5) (Fig. 1). Members of this 
family were recruited from 1994 through 1997. 
Blood lipid levels were measured at multiple time 
points from 1994 through 2003; averages of the 
measurements were used in analyses. The last fol-
low-up visit occurred in 2003; at that time, none 
of the family members had a history of coronary 
heart disease, and the oldest member was 81 years 
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Figure 1. Pedigree of the Study Family with Familial Combined Hypolipidemia.
Squares indicate male family members, and circles female family members. Slashes indicate deceased persons. Roman numerals to the 
left of the pedigree indicate the generation; numerals to the upper left of each symbol indicate the individual family member. For the 
ANGPTL3 genotype, the X denotes a stop codon. The column of five values under each symbol indicates, from top to bottom, the age in 
years (as of 1997) and the total cholesterol, triglyceride, and LDL and HDL cholesterol levels (all in milligrams per deciliter). The values 
are the means of measurements from multiple fasting lipid profiles. To convert values for cholesterol to millimoles per liter, multiply by 
0.02586. To convert values for triglycerides to millimoles per liter, multiply by 0.01129.
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of age. Selected family members underwent lipo-
protein metabolic studies and magnetic resonance 
spectroscopic measurements of hepatic fat.8,12
DNA samples were available from 38 members 
across three generations. Full lipid profiles, in-
cluding apolipoprotein B levels, of these family 
members are listed in Table 1 in the Supplemen-
tary Appendix, available with the full text of this 
article at NEJM.org. Several family members had 
low plasma levels of LDL cholesterol and triglyc-
erides. Four persons in the second generation 
(Participants II.2, II.4, II.5, and II.6) had com-
bined hypolipidemia, with extremely low fasting 
plasma levels of LDL cholesterol, triglycerides, and 
HDL cholesterol. Two of the siblings with com-
bined hypolipidemia (Participants II.4 and II.5) 
underwent exome sequencing.
Statistical modeling of genotypes and pheno-
types (lipid and lipoprotein metabolic phenotypes) 
consisted of linear regression performed with the 
use of R software (www.r-project.org). “Residual” 
lipid phenotypes were ascertained after adjustment 
for age, age squared, and sex. The institutional 
review boards at the Washington University in 
St. Louis School of Medicine and the Broad Insti-
tute approved the study protocols. All participants 
provided written informed consent.
Exome Sequencing, Sanger Sequencing,  
and Linkage Analyses
A solution hybrid selection method13 was used to 
isolate DNA of the exome, which was subjected 
to sequencing (on the Genome Analyzer II plat-
form; Illumina). Sixty exomes from persons of 
European descent, sequenced with the same meth-
ods, were used as controls. The full methods 
used for exome sequencing, Sanger sequencing, 
and linkage analysis are described in the Supple-
mentary Appendix.
Replication
The sequencing of ANGPTL3 in participants in the 
Dallas Heart Study has been described previously.14 
Statistical modeling of genotypes and phenotypes 
was performed with the use of linear regression 
analysis involving adjustment for age, sex, race or 
Table 1. Details of Solution Hybrid Selection, and Results of Exome Sequencing, in Two Study Participants.*
Sample Participant II.4 Participant II.5
No. of bait DNA bases 37,640,396 37,640,396
No. of target DNA bases 28,646,006 28,646,006
Total bases sequenced — no. (%) 10,529,696,342 9,902,941,465
Outside bait region 2,062,882,735 (19.6) 1,905,438,918 (19.2)
Near bait region 1,090,792,362 (10.4) 943,516,981 (9.5)
Within bait region 7,376,021,245 (70.0) 7,053,985,566 (71.2)
Within target region 6,007,508,537 (57.1) 5,793,926,100 (58.5)
Coverage†
Within bait region 196 187
Within target region 210 202
Base covered ≥10 times — % of region 93.4 92.1
Base covered ≥20 times — % of region 90.1 88.0
Identified variants‡
Total no. 18,259 18,123
Transition-to-transversion ratio 2.93 2.98
No. of variants meeting quality-control standard 16,426 16,246
No. in dbSNP 15,680 15,512
Concordance with dbSNP — % 99.50 99.52
No. not in dbSNP 746 734
No. not in 1000 Genomes Project database 481 481
No. not in the 60 control exomes 266 277
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ethnic group, and treatment for hypercholester-
olemia.
R esult s
Exome Sequencing
A total of 28,646,006 bases in 164,688 exons from 
15,994 genes were targeted for sequencing (Ta-
ble 1). For each of the two participants, we gen-
erated approximately 6 billion bases of sequence, 
allowing each targeted base to be read approxi-
mately 200 times. For each participant, approxi-
mately 270 new single-nucleotide variants were 
found, of which approximately 150 were missense 
mutations and approximately 6 were nonsense 
(premature termination) mutations (Table 1).
Nonsense Variants in ANGPTL3
To identify the causal variants in the two partici-
pants who underwent sequencing (Participants 
II.4 and II.5), we hypothesized that the phenotype 
of combined hypolipidemia (i.e., the concurrence 
of low levels of plasma HDL cholesterol, LDL cho-
lesterol, and triglycerides) was inherited in an auto-
somal recessive fashion. Therefore, we sought 
genes harboring novel variants in both alleles of 
both participants. We eliminated variants whose 
features did not meet quality-control standards 
(see the Supplementary Appendix) and variants that 
were not shared between the two probands. We 
also eliminated any variant sites that were pres-
ent in the Single Nucleotide Polymorphism Data-
base (dbSNP, build 130) of the National Center 
Table 1. (Continued.)
Sample Participant II.4 Participant II.5
Coding single-nucleotide variants
Known
Total — no. 16,160 15,969
Transition-to-transversion ratio 3.20 3.26
Homozygous — no. 6284 6419
Heterozygous — no. 9876 9550
Synonymous — no. 9260 9179
Missense — no. 6622 6525
Premature termination — no. 40 41
Splice site — no. 238 224
Novel
Total — no. 266 277
Transition-to-transversion ratio 2.86 2.85
Homozygous — no. 6 7
Heterozygous — no. 260 270
Synonymous — no. 107 116
Missense — no. 151 149
Premature termination — no. 5 7
Splice site — no. 3 4
No. of genes with novel homozygous or compound hetero-
zygous variants shared between participants§
1 1
* The bait DNA is the region of the genome preferentially retained during the hybrid selection step; it is therefore vastly 
enriched during sequencing, as compared with unselected regions. The target DNA is the subgroup of the bait DNA 
that is of special interest — in this study, the 164,688 exon sequences with additional two-nucleotide flanking sequenc-
es, to capture splice sites.
† “Coverage” is the average number of times each base is represented in the sequence reads, as a measure of the degree 
to which the region of interest is captured by the sequencing method. 
‡ The term dbSNP refers to the Single Nucleotide Polymorphism Database (build 130) of the National Center for Biotech-
nology Information.
§ The one shared gene is ANGPTL3.
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for Biotechnology Information, in the genomes 
sequenced by the 1000 Genomes Project, or in 
the 60 control exomes (Table 1).
Only one gene harbored novel variants in both 
alleles in both siblings: ANGPTL3. ANGPTL3 har-
bored two nonsense variants: a single-nucleotide 
variant (GAA→TAA, at nucleotide 62,836,210 on 
chromosome 1) that introduces a nonsense mu-
tation at position 129, resulting in the amino 
acid mutation E129X; and a double nucleotide 
variant (TCC→TGA, at nucleotides 62,835,875 to 
62,835,876 on chromosome 1) that introduces a 
nonsense mutation at position 17, resulting in the 
amino acid mutation S17X. (The X in both amino 
acid mutations denotes a stop codon.) Both mu-
tations are located in the first exon of ANGPTL3 
(Fig. 1 in the Supplementary Appendix).
Sanger sequencing of the first ANGPTL3 exon 
of all 38 persons in the study family who were 
available confirmed that the two nonsense mu-
tations segregated independently (Fig. 1). The 13 
family members heterozygous for just one of the 
two nonsense mutations had significantly lower 
plasma levels of LDL cholesterol (mean, 72 mg per 
deciliter [1.9 mmol per liter]) and triglycerides 
(mean, 64 mg per deciliter [0.7 mmol per liter]) 
than did the 21 family members with neither mu-
tation (mean for LDL cholesterol, 109 mg per 
deciliter; P<0.001; mean for triglycerides, 130 mg 
per deciliter; P = 0.01). The remaining 4 partici-
pants were compound heterozygotes and had even 
lower plasma LDL cholesterol and triglyceride 
levels (means, 33 mg per deciliter [0.9 mmol per 
liter] and 21 mg per deciliter [0.2 mmol per liter], 
respectively). Thus, the nonsense mutations in 
ANGPTL3 affected phenotypes in a manner depen-
dent on the gene dosage — the number of alleles 
present in a given person (P<0.001 for LDL cho-
lesterol and P = 0.004 for triglycerides, from addi-
tive models) (Fig. 2).
In contrast, the nonsense mutations were re-
cessive with respect to HDL cholesterol: family 
members heterozygous for a single nonsense mu-
tation had plasma HDL cholesterol levels (mean, 
43 mg per deciliter [1.1 mmol per liter]) that did 
not differ significantly from those of family mem-
bers with no ANGPTL3 mutation (mean, 46 mg per 
deciliter [1.2 mmol per liter]; P = 0.34), whereas 
compound heterozygotes had a very low level of 
HDL cholesterol (mean, 18 mg per deciliter [0.5 
mmol per liter]; P<0.001 from a recessive model). 
These relations were maintained even after ad-
justment of lipid levels for age and sex (Fig. 2).
Linkage Analyses
To determine whether mutations at another lo-
cus could account for the hypolipidemia in this 
family, we performed linkage analyses, using LDL 
cholesterol and HDL cholesterol as quantitative 
traits. The highest lod scores for both traits oc-
curred between the DNA markers GATA72H07 
and GATA109 on chromosome 1p33–31.1, the re-
gion harboring ANGPTL3. The peak lod scores for 
LDL cholesterol were 3.07 (at GATA165C03) and 
3.89 (at GATA61A06) (Table 2 in the Supplemen-
tary Appendix). Significant lod scores were not 
found for regions on chromosomes 3 and 10 pre-
viously reported to be associated with familial hy-
pobetalipoproteinemia,6,7 nor for any other regions 
in the genome. These results provide additional 
evidence that the nonsense mutations in ANGPTL3 
are causal for the combined hypolipidemia in this 
family. Additional details regarding the linkage 
analyses are given in the Supplementary Appendix.
Replication in a Population-Based Cohort
Sequencing of ANGPTL3 in participants in the Dal-
las Heart Study14 showed that carriers of frame-
shift mutations had significantly lower LDL cho-
lesterol levels than noncarriers. Details regarding 
these analyses are given in the Supplementary 
Appendix.
Studies of Lipoprotein Metabolism
Physiological studies of selected members of the 
study family indicated that carriers of ANGPTL3 
mutations had decreased rates of VLDL produc-
tion and increased rates of LDL fractional catab-
olism. Details regarding these analyses are given 
in the Supplementary Appendix.
Discussion
Whole-exome sequencing in two siblings with a 
clinical syndrome of combined hypolipidemia re-
vealed two independent nonsense mutations in 
ANGPTL3. One, S17X, is predicted to terminate 
translation near the N-terminal of the protein; the 
other, E129X, is predicted to prematurely termi-
nate the protein at residue 129. Family members 
who were heterozygous for either mutation had 
plasma levels of LDL cholesterol and triglycerides 
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that were intermediate between the levels in per-
sons with neither mutation and those with both 
mutations, findings consistent with a codominant 
mode of inheritance for the LDL cholesterol and 
triglyceride phenotypes. In contrast, the level of 
HDL cholesterol appears to segregate as a reces-
sive trait. Family members who had both non-
sense alleles, but not members with just one, had 
significantly lower plasma HDL cholesterol levels 
than members with neither mutation. Thus, per-
sons with the two nonsense ANGPTL3 alleles had 
low plasma levels of LDL cholesterol, triglycerides, 
and HDL cholesterol, a phenotype we propose to 
call familial combined hypolipidemia.
The protein ANGPTL3 is secreted and ex-
pressed primarily in the liver. The underlying gene 
was originally associated with lipid levels on the 
basis of positional cloning of a causal mutation in 
a hypolipidemic mouse strain.15 Expression of the 
recombinant protein in the livers of these mice 
increased plasma triglyceride and cholesterol lev-
els. Subsequent studies showed that targeted in-
activation of Angptl3 in mice lowered plasma 
cholesterol and triglyceride levels — both in wild-
type mice,16 in which cholesterol is transported 
primarily in HDL particles, and in mice in which 
Apoe or Ldlr (the LDL receptor gene) had been 
knocked out,17,18 in which cholesterol is carried 
primarily by VLDL, intermediate-density lipopro-
tein, and LDL. Taken together, these data sug-
gest that ANGPTL3 normally acts to increase 
plasma levels of triglycerides, LDL cholesterol, and 
HDL cholesterol.
This conclusion is consistent with the finding 
of combined hypolipidemia in persons with two 
defective ANGPTL3 alleles. The activities of lipo-
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Figure 2. Phenotypes Associated with Familial Combined Hypolipidemia in the Study Family, According to Number of Mutant 
ANGPTL3 Alleles.
Shown are the levels of low-density lipoprotein (LDL) cholesterol (Panel A), triglycerides (Panel B), and high-density lipoprotein (HDL) 
cholesterol (Panel C) in the family members, grouped according to ANGPTL3 genotype. The corresponding “residual” phenotypes are 
shown (in Panels D, E, and F, respectively), in units normalized to the standard deviation, after adjustment for age, age squared, and sex. 
The box plots give the median levels (middle horizontal line in each box), the interquartile ranges (delineated by the top and bottom of 
each box), and outliers falling below the 5th percentile or above the 95th percentile (points below or above the vertical lines, respectively). 
To convert values for cholesterol to millimoles per liter, multiply by 0.02586. To convert values for triglycerides to millimoles per liter, 
multiply by 0.01129.
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protein lipase and endothelial lipase, key enzymes 
in the metabolism of circulating triglycerides and 
HDL cholesterol, respectively, are elevated in 
Angptl3-knockout mice,19-21 suggesting that in-
creased activity of these enzymes may explain the 
low levels of triglycerides and HDL cholesterol in 
humans with ANGPTL3 nonsense mutations. The 
mechanism by which deficiency of ANGPTL3 low-
ers LDL cholesterol remains to be determined.
Confirming the link between ANGPTL3 and 
plasma LDL cholesterol levels is the finding that 
Dallas Heart Study participants with frameshift 
mutations had significantly lower LDL cholesterol 
levels than the rest of the cohort. Furthermore, in 
genomewide association screening of common 
variants in more than 100,000 participants, we 
found that polymorphisms near ANGPTL3 are 
highly significantly associated with lipid traits — 
most strongly with the triglyceride level (e.g., 
the polymorphism rs2131925, associated with a 
change of 4.9 mg per deciliter [0.05 mmol per liter] 
per allele [P = 9×10−43 for the association]), but also 
with the LDL cholesterol level (e.g., rs2131925, 
associated with a change of 1.6 mg per deciliter 
[0.04 mmol per liter] per allele [P = 2×10−17 for the 
association]). These two associations were consis-
tent with the lipid patterns observed in the cur-
rent family under study.22
This contrasts with studies of common variants 
near LPL (the gene encoding lipoprotein lipase), 
which are associated with triglycerides and HDL 
cholesterol, and those near LIPG (encoding endo-
thelial lipase), which are associated with HDL 
cholesterol; neither the LPL variants nor the LIPG 
variants are associated with LDL cholesterol.22 
These studies are consistent with observations in 
genetically modified mice that effects of ANGPTL3 
on triglycerides and HDL cholesterol are medi-
ated by lipoprotein lipase and endothelial lipase, 
respectively, and that the mechanism by which 
ANGPTL3 modulates plasma LDL cholesterol 
levels is distinct.
The apparent discrepancy between the modes 
of inheritance of reduced LDL cholesterol and tri-
glyceride levels and reduced HDL cholesterol levels 
also argues for distinct mechanisms of action on 
different lipoproteins. We found that carriers of 
ANGPTL3 nonsense mutations had decreased rates 
of VLDL apolipoprotein B production and in-
creased fractional catabolic rates for LDL apoli-
poprotein B. This suggests that ANGPTL3 acts 
directly in the liver to regulate hepatocellular li-
poprotein secretion and clearance, which is dis-
tinct from the role of the protein in the inhibi-
tion of lipoprotein lipase and endothelial lipase 
in the bloodstream.
In conclusion, we found that nonsense muta-
tions in ANGPTL3 resulted in decreased plasma 
LDL cholesterol levels and, in persons harboring 
two nonsense alleles, a phenotype of familial com-
bined hypolipidemia. This finding highlights the 
promise of exome sequencing in medical genet-
ics. It also underscores a new mechanism for the 
lowering of LDL cholesterol in humans.
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